Oncogenic mutations of XPO1 can also associate with a negatively impacted immune system, with a study of germinal center B-cell (GCB)-DLBCL patients showing that those with a gain-of-function mutation in XPO1 possessed lymphodepleted microenvironments [35]. This evidence concerns the gene XPO1 and diffuse large B-cell lymphoma.